Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,178 across all filing types
Latest filing 2024-01-11 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the request for stop transfer, addressed to stock exchanges. The document is short (2896 characters), formal, and serves as a regulatory compliance communication rather than a financial report or announcement of voting results, management changes, or capital changes. It does not contain financial data, earnings, or management discussion. It is not a report publication announcement but a regulatory filing to comply with stock exchange requirements. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-01-11 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the request for stop transfer, addressed to stock exchanges. The document is short (2896 characters) and is a regulatory compliance communication rather than a financial report or announcement of voting results, management changes, or capital changes. It does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-01-11 English
Lupin Launches Varenicline Tablets in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of Varenicline Tablets in the United States after receiving FDA approval. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which pertains to material events or information. The document is short (3845 characters) and primarily serves as a regulatory disclosure of a business update rather than a financial report or detailed investor presentation. It does not contain financial statements, management discussion, or detailed financial data. Therefore, it fits best under the category of Regulatory Filings (RNS), which is used for general regulatory announcements and disclosures that do not fit other specific categories.
2024-01-10 English
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the launch of Varenicline Tablets in the United States after receiving FDA approval. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which pertains to material events or information. The document does not contain financial statements, detailed financial analysis, or comprehensive report content. It is a corporate announcement about a product launch and regulatory approval, not a financial report or detailed investor presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP) as it relates to a significant business development that could impact the company's financial position and market perception, but it is not a full financial report or earnings release. The document length is short (3842 characters), and it is not merely announcing the publication of a report but is itself the disclosure. Hence, the classification is CAP with high confidence.
2024-01-10 English
Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in the United states.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Bromfenac Ophthalmic Solution) following FDA approval. It is addressed to stock exchanges under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which pertains to disclosures about material events or information. The document does not contain financial statements, detailed financial analysis, or management discussion. It is a regulatory disclosure about a business event rather than a financial report or earnings release. The document length is 4122 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-09 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Bromfenac Ophthalmic Solution) after receiving FDA approval. It is addressed to stock exchanges under SEBI Listing Regulations, indicating a regulatory disclosure. The content is promotional and informative about a product launch, not a financial report, earnings release, or management discussion. The document length is 4122 characters, which is relatively short and typical for a press release. It does not contain financial statements, voting results, or management changes. It is not a report itself but a disclosure announcement. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2024-01-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.